

Paolo A Ascierto

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6378051/paolo-a-ascierto-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

569
papers

48,709
citations

86
h-index

212
g-index

671
ext. papers

61,915
ext. citations

7.1
avg. IF

7.25
L-index

#	Paper	IF	Citations
569	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 23-34	59.2	5047
568	Nivolumab in previously untreated melanoma without BRAF mutation. <i>New England Journal of Medicine</i> , 2015 , 372, 320-30	59.2	3809
567	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
566	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 375-84	21.7	1881
565	Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 1867-76	59.2	1403
564	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1535-1546	59.2	1260
563	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1824-1835	59.2	1178
562	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 908-18	21.7	1151
561	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1789-1801	59.2	918
560	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018 , 391, 2128-2139	40	910
559	Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. <i>Journal of Pathology</i> , 2014 , 232, 199-209	9.4	882
558	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016 , 375, 1845-1855	59.2	870
557	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 522-30	21.7	842
556	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1-10	2.2	786
555	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 883-895	21.7	783
554	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology, The</i> , 2014 , 15, 323-32	21.7	753
553	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 1087-95	21.7	708

552	Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1248-60	21.7	590
551	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012 , 10, 205	8.5	538
550	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. <i>Lancet Oncology, The</i> , 2013 , 14, 249-56	21.7	487
549	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018 , 33, 853-861.e4	24.3	471
548	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 603-615	21.7	451
547	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016 , 22, 5487-5496	12.9	373
546	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016 , 22, 2908-18	12.9	372
545	BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2522-9	2.2	353
544	Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3205-11	2.2	343
543	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. <i>European Journal of Cancer</i> , 2017 , 81, 116-129	7.5	314
542	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 611-622	21.7	306
541	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2836-2844	2.2	296
540	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1315-1327	21.7	291
539	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>Oncolmmunology</i> , 2014 , 3, e28780	7.2	259
538	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 435-445	21.7	240
537	Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. <i>Clinical Cancer Research</i> , 2005 , 11, 1835-41	12.9	235
536	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 879-86	21.7	232
535	Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. <i>Annals of Oncology</i> , 2016 , 27, 732-8	10.3	229

534	Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. <i>Seminars in Oncology</i> , 2010 , 37, 508-16	5.5	220
533	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology, The</i> , 2014 , 15, 436-44	21.7	206
532	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 675-83	7.4	205
531	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2020 , 395, 1835-1844	40	204
530	Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7660-8	2.2	191
529	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up□ <i>Annals of Oncology</i> , 2019 , 30, 1884-1901	10.3	182
528	Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. <i>European Journal of Cancer</i> , 2017 , 83, 247-257	7.5	181
527	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2017 , 23, 1929-1936	12.9	181
526	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. <i>JAMA Oncology</i> , 2019 , 5, 187-194	13.4	173
525	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab 2018 , 6, 74		166
524	Vismodegib in patients with advanced basal cell carcinoma (STEVE): a pre-planned interim analysis of an international, open-label trial. <i>Lancet Oncology, The</i> , 2015 , 16, 729-36	21.7	161
523	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. <i>Nature Medicine</i> , 2019 , 25, 941-946	50.5	160
522	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 2019 , 7, 57		155
521	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 519-527	13.4	148
520	Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVE, an international, open-label trial. <i>European Journal of Cancer</i> , 2017 , 86, 334-348	7.5	146
519	Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. <i>Clinical Cancer Research</i> , 2013 , 19, 997-1008	12.9	144
518	Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2220-6	2.2	144
517	Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1465-1477	21.7	140

516	Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti- PD-1 /PD-L1 therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9520-9520	2.2	136
515	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 867-875	2.2	135
514	Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , 2014 , 12, 116	8.5	130
513	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. <i>Annals of Oncology</i> , 2017 , 28, 2581-2587	10.3	129
512	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014 , 50, 121-7	7.5	126
511	Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 510-520	21.7	123
510	Main roads to melanoma. <i>Journal of Translational Medicine</i> , 2009 , 7, 86	8.5	122
509	Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. <i>Annals of Oncology</i> , 2020 , 31, 1320-1335	10.3	121
508	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016 , 53, 125-34	7.5	115
507	Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. <i>Clinical Cancer Research</i> , 2013 , 19, 1009-20	12.9	113
506	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1608-1616	2.2	108
505	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016 , 22, 4848-4858	12.9	108
504	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017 , 86, 37-45	7.5	106
503	Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. <i>Annals of Oncology</i> , 2013 , 24, 2911-5	10.3	102
502	Human melanoma metastases express functional CXCR4. <i>Clinical Cancer Research</i> , 2006 , 12, 2427-33	12.9	102
501	Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 304-11	2.2	102
500	The influence of diet on anti-cancer immune responsiveness. <i>Journal of Translational Medicine</i> , 2018 , 16, 75	8.5	100
499	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. <i>Annals of Oncology</i> , 2015 , 26, 798-803	10.3	100

498	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. <i>Drugs</i> , 2016 , 76, 925-45	12.1	100
497	NF- κ B as potential target in the treatment of melanoma. <i>Journal of Translational Medicine</i> , 2012 , 10, 53	8.5	99
496	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 426-435	8.9	96
495	Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. <i>Nature Communications</i> , 2020 , 11, 2168	17.4	95
494	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3003-3003	2.2	94
493	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. <i>Journal of Translational Medicine</i> , 2012 , 10, 107	8.5	93
492	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , 2019 , 29, 846-861	24.7	91
491	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014 , 118, 109-16	4.8	90
490	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , 2019 , 20, e378-e389	21.7	88
489	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.. <i>New England Journal of Medicine</i> , 2022 , 386, 24-34	59.2	88
488	Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). <i>Annals of Oncology</i> , 2018 , 29, 2163-2174	10.3	88
487	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. <i>Oncologist</i> , 2016 , 21, 1218-1229	5.7	86
486	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3947-3970	2.2	82
485	Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. <i>Journal of Clinical Oncology</i> , 2003 , 21, 767-73	2.2	81
484	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist</i> , 2019 , 24, e327-e337	5.7	80
483	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019 , 119, 1-10	7.5	79
482	Mucosal melanoma of the head and neck. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 112, 136-152	7	78
481	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge Napoli, December 5th 2015 2016 , 4,		78

480	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3925-3936	2.2	78
479	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO) 2016 , 4,		78
478	Immuno-oncology combinations: a review of clinical experience and future prospects. <i>Clinical Cancer Research</i> , 2014 , 20, 6258-68	12.9	76
477	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014 , 33, 30	12.8	76
476	PD-L1 expression as a potential predictive biomarker. <i>Lancet Oncology, The</i> , 2015 , 16, 1285-7	21.7	75
475	MicroRNAs in melanoma development and resistance to target therapy. <i>Oncotarget</i> , 2017 , 8, 22262-22278	3.8	74
474	Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. <i>Cancer Investigation</i> , 2014 , 32, 144-9	2.1	74
473	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. <i>European Journal of Cancer</i> , 2020 , 126, 33-44	7.5	74
472	MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors. <i>American Journal of Clinical Dermatology</i> , 2017 , 18, 745-754	7.1	72
471	Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 781-91	7.4	72
470	Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. <i>Journal of Immunotoxicology</i> , 2012 , 9, 241-7	3.1	70
469	Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3831-7	2.2	70
468	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 393-403	21.7	69
467	miR-579-3p controls melanoma progression and resistance to target therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E5005-13	11.5	69
466	Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. <i>Annals of Oncology</i> , 2016 , 27, 1940-6	10.3	67
465	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8502-8502	2.2	65
464	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021 , 27, 301-309	50.5	65
463	Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior antiPD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. <i>Annals of Oncology</i> , 2017 , 28, 1111-1118	10.3	64

462	Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. <i>Journal of Translational Medicine</i> , 2013 , 11, 145	8.5	64
461	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial. <i>Journal of Translational Medicine</i> , 2020 , 18, 405	8.5	64
460	Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. <i>European Journal of Surgical Oncology</i> , 2016 , 42, 1914-1923	2.6	63
459	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018 , 104, 137-144	7.5	63
458	Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. <i>Frontiers in Oncology</i> , 2015 , 5, 183	5.3	62
457	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017 , 73, 61-70	7.5	59
456	Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1437-43	2.2	59
455	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 643-654	21.7	58
454	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events 2021 , 9,		58
453	The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response 2020 , 8,		56
452	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. <i>Onc Immunology</i> , 2018 , 7, e1387706	7.2	56
451	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. <i>Journal of Translational Medicine</i> , 2017 , 15, 46	8.5	55
450	Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2017 , 15, 244	8.5	55
449	Adjuvant therapy of melanoma with interferon: lessons of the past decade. <i>Journal of Translational Medicine</i> , 2008 , 6, 62	8.5	55
448	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. <i>European Journal of Cancer</i> , 2018 , 91, 116-124	7.5	54
447	Nivolumab (nivo) + ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8503-8503	2.2	54
446	Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. <i>Annals of Oncology</i> , 2017 , 28, 1137-1144	10.3	53
445	Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy 2020 , 8,		53

444	Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial. <i>Annals of Oncology</i> , 2019 , 30, v533-v534	10.3	52
443	Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018 , 9, 552	8.4	51
442	Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. <i>Journal of Translational Medicine</i> , 2013 , 11, 180	8.5	51
441	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. <i>Oncolmmunology</i> , 2015 , 4, e1008842	7.2	50
440	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology, The</i> , 2014 , 15, 297-304	21.7	49
439	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020 , 31, 1435-1448	10.3	49
438	MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With Mutation Detected in Circulating-Free DNA. <i>Frontiers in Pharmacology</i> , 2018 , 9, 856	5.6	49
437	Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. <i>Journal of Translational Medicine</i> , 2013 , 11, 135	8.5	48
436	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1794-1806	8.9	47
435	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 2020 , 8,		47
434	BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 286-92	2.2	47
433	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3638-3651	2.2	47
432	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. <i>Oncolmmunology</i> , 2017 , 6, e1261242	7.2	46
431	Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3500-3500	7.2	46
430	Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1944-1956	4.6	46
429	A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2018 , 6, 79-86	12.5	46
428	Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. <i>Melanoma Research</i> , 2005 , 15, 235-44	3.3	45
427	Nivolumab + ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4014-4014	2.2	44

426	Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 1015-34	7.4	44
425	The use of interferon in melanoma patients: a systematic review. <i>Cytokine and Growth Factor Reviews</i> , 2015 , 26, 203-12	17.9	43
424	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9502-9502	2.2	43
423	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019 , 116, 148-157	7.5	42
422	Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. <i>JAMA Oncology</i> , 2018 , 4, 1382-1388	13.4	42
421	KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. <i>Annals of Oncology</i> , 2018 , 29, viii442	10.3	42
420	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop 2019 , 7, 131		41
419	2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond. <i>EBioMedicine</i> , 2015 , 2, 92-3	8.8	41
418	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020 , 128, 17-26	7.5	41
417	CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4010-4010	2.2	41
416	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020 , 26, 1557-1563	50.5	41
415	Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. The Melanoma Cooperative Study. <i>British Journal of Dermatology</i> , 2000 , 142, 893-8	4	40
414	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020 , 130, 126-138	7.5	39
413	Serious haematological toxicity during and after ipilimumab treatment: a case series. <i>Journal of Medical Case Reports</i> , 2014 , 8, 240	1.2	39
412	Clinical genetic testing for familial melanoma in Italy: a cooperative study. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, 775-82	4.5	39
411	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102229	2.2	39
410	Five-Year Outcomes With Nivolumab in Patients With Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3937-3946	2.2	39
409	Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. <i>BMC Cancer</i> , 2013 , 13, 564	4.8	38

408	Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. <i>Journal of Translational Medicine</i> , 2010 , 8, 76	8.5	38
407	Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 318	12.8	38
406	Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. <i>Oncotarget</i> , 2017 , 8, 8890-8899	3.3	37
405	Immunological effects of BRAF+MEK inhibition. <i>OncImmunity</i> , 2018 , 7, e1468955	7.2	37
404	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in -mutant melanoma 2020 , 8,		37
403	A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9007-9007	2.2	37
402	Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. <i>BioDrugs</i> , 2017 , 31, 51-61	7.9	36
401	HOTAIR role in melanoma progression and its identification in the blood of patients with advanced disease. <i>Journal of Cellular Physiology</i> , 2017 , 232, 3422-3432	7	36
400	Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. <i>Annals of Oncology</i> , 2017 , 28, 1672-1673	10.3	36
399	Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 735-746	5.4	36
398	LBA43 Spatalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600E mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. <i>Annals of Oncology</i> , 2020 , 31, S1172	10.3	36
397	Proportions of blood-borne V β 1+ and V β 2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2016 , 64, 116-26	7.5	36
396	Genetic alterations in main candidate genes during melanoma progression. <i>Oncotarget</i> , 2018 , 9, 8531-8541	5.1	35
395	Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. <i>ESMO Open</i> , 2016 , 1, e000068	6	34
394	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 97-107	7.4	34
393	What's new in melanoma? Combination!. <i>Journal of Translational Medicine</i> , 2015 , 13, 213	8.5	33
392	The role of MEK inhibitors in the treatment of metastatic melanoma. <i>Current Opinion in Oncology</i> , 2014 , 26, 196-203	4.2	33
391	Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. <i>BMC Cancer</i> , 2009 , 9, 352	4.8	33

390	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2021 , 22, 836-847	21.7	33
389	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019 , 119, 168-178	7.5	32
388	AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. <i>Journal of Translational Medicine</i> , 2014 , 12, 216	8.5	32
387	Electrochemotherapy as "new standard of care" treatment for cutaneous Kaposi's sarcoma. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 61-6	3.6	32
386	CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1589-95	7.4	32
385	Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. <i>Melanoma Research</i> , 2003 , 13, 167-70	3.3	32
384	Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?. <i>Journal of Translational Medicine</i> , 2017 , 15, 17	8.5	31
383	Increased HOX C13 expression in metastatic melanoma progression. <i>Journal of Translational Medicine</i> , 2012 , 10, 91	8.5	31
382	Unexpected distribution of cKIT and BRAF mutations among southern Italian patients with sinonasal melanoma. <i>Dermatology</i> , 2013 , 226, 279-84	4.4	31
381	Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9006-9006	2.2	31
380	Gene Expression Profiling in -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. <i>Clinical Cancer Research</i> , 2017 , 23, 5238-5245	12.9	30
379	Interleukin 18: friend or foe in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013 , 1836, 296-303	30.3	30
378	Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. <i>British Journal of Dermatology</i> , 2008 , 158, 243-50	4	30
377	Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9503-9503	2.2	30
376	Frontline Therapy for -Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 564-571	7.1	29
375	Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program 2020 , 8,		29
374	Antitumor Activity of BRAF Inhibitor and IFN β Combination in BRAF-Mutant Melanoma. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	29
373	Novel approaches in melanoma prevention and therapy. <i>Cancer Treatment and Research</i> , 2014 , 159, 443-55	55	29

372	NEMO-binding domain peptide inhibits proliferation of human melanoma cells. <i>Cancer Letters</i> , 2009 , 274, 331-6	9.9	29
371	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. <i>European Journal of Cancer</i> , 2020 , 125, 114-120	7.5	29
370	Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. <i>British Journal of Cancer</i> , 2016 , 115, 1280-1284	8.7	29
369	Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. <i>Cell Death and Differentiation</i> , 2019 , 26, 1267-1282	12.7	29
368	Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. <i>BMC Cancer</i> , 2013 , 13, 17	4.8	28
367	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. <i>Journal of Translational Medicine</i> , 2013 , 11, 202	8.5	28
366	Microenvironment and tumor progression of melanoma: new therapeutic perspectives. <i>Journal of Immunotoxicology</i> , 2013 , 10, 235-52	3.1	28
365	Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 85, 149-61	7	28
364	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. <i>Journal of Translational Medicine</i> , 2014 , 12, 291	8.5	28
363	NF-B is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. <i>Journal of Translational Medicine</i> , 2012 , 10, 252	8.5	28
362	Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6-6	2.2	28
361	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 474, 421-432	5.1	28
360	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 3671-3681	12.9	27
359	PD-L1 inhibitors in the pipeline: Promise and progress. <i>OncImmunity</i> , 2017 , 7, e1365209	7.2	27
358	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019 , 119, 97-106	7.5	27
357	Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8511-8511	2.2	27
356	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. <i>JAMA Oncology</i> , 2020 , 6, 1256-1264	12.4	27
355	Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 259-266	3.8	27

354	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021 , 142, 18-28	7.5	27
353	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. <i>Oncology</i> , 2018 , 7, e1405206	7.2	27
352	The immune-related role of BRAF in melanoma. <i>Molecular Oncology</i> , 2015 , 9, 93-104	7.9	26
351	Issues affecting molecular staging in the management of patients with melanoma. <i>Journal of Cellular and Molecular Medicine</i> , 2007 , 11, 1052-68	5.6	26
350	The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600E mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9531-9531	2.2	26
349	Prognostic value of serum VEGF in melanoma patients: a pilot study. <i>Anticancer Research</i> , 2004 , 24, 4255-8	5.8	26
348	Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis. <i>Journal of Translational Medicine</i> , 2017 , 15, 82	8.5	25
347	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013 , 11, 161	8.5	25
346	Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. <i>Future Oncology</i> , 2015 , 11, 703-12	3.6	25
345	Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. <i>European Journal of Cancer</i> , 2007 , 43, 137-43	7.5	25
344	An assessment of factors related to tumor thickness and delay in diagnosis of melanoma in southern Italy. <i>Preventive Medicine</i> , 2002 , 35, 271-7	4.3	25
343	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. <i>Frontiers in Oncology</i> , 2015 , 5, 152	5.3	24
342	Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. <i>Journal of Medical Case Reports</i> , 2012 , 6, 131	1.2	24
341	Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9519-9519	2.2	24
340	Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. <i>European Journal of Cancer</i> , 2017 , 79, 176-184	7.5	23
339	A phase II study of the L191L2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1547-1559	7.4	23
338	Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. <i>International Journal of Cardiology</i> , 2019 , 292, 171-179	3.2	23
337	Genomic Features of Exceptional Response in Vemurafenib + Cobimetinib-treated Patients with -mutated Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019 , 25, 3239-3246	12.9	23

336	Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. <i>Annals of Oncology</i> , 2017 , 28, v429-v430	10.3	23
335	Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. <i>Oncotarget</i> , 2015 , 6, 24823-41	3.3	23
334	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020 , 16, 4429-4438	3.6	23
333	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 765-772	7.4	23
332	Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. <i>European Journal of Cancer</i> , 2018 , 97, 7-15	7.5	23
331	Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone. <i>Annals of Oncology</i> , 2017 , 28, v428	10.3	22
330	Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. <i>Journal of Translational Medicine</i> , 2017 , 15, 146	8.5	22
329	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA9008-LBA9008	2.2	22
328	Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9500-9500	2.2	22
327	Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. <i>Oncolimmunology</i> , 2017 , 6, e1283462	7.2	21
326	Discrepant alterations in main candidate genes among multiple primary melanomas. <i>Journal of Translational Medicine</i> , 2014 , 12, 117	8.5	21
325	Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. <i>Journal of Translational Medicine</i> , 2012 , 10, 131	8.5	21
324	Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9522-9522	2.2	21
323	Accumulation of Circulating CCR7 Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. <i>Cancer Immunology Research</i> , 2019 , 7, 841-852	12.5	20
322	Cd40 Activation as Potential Tool in Malignant Neoplasms. <i>Tumori</i> , 2002 , 88, 361-366	1.7	20
321	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. <i>Nature Communications</i> , 2020 , 11, 6262	17.4	20
320	Sun exposure and melanoma prognostic factors. <i>Oncology Letters</i> , 2016 , 11, 2706-2714	2.6	20
319	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition 2021 , 9,		20

318	Emerging Strategies in Systemic Therapy for the Treatment of Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 751-758 ¹	20
317	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 2020 , 8,	19
316	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019 , 121, 144-153	7.5 19
315	Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon- β in advanced malignant melanoma. <i>Journal of Translational Medicine</i> , 2013 , 11, 38	8.5 19
314	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017 , 8, 386	8.4 19
313	Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 271-4	7.4 19
312	Expression of the anti-apoptotic protein BAG3 in human melanomas. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 252-4	4.3 19
311	Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. <i>BMC Cancer</i> , 2006 , 6, 266	4.8 19
310	Cisplatin, dacarbazine, and fotemustine plus interferon β in patients with advanced malignant melanoma. <i>Cancer</i> , 2000 , 89, 2630-2636	6.4 19
309	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9504-9504 ²	2.2 19
308	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020 , 31, 1449-1461	10.3 19
307	Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). <i>Annals of Oncology</i> , 2016 , 27, 1947-53	10.3 18
306	Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. <i>Lancet Oncology, The</i> , 2016 , 17, 1037-1039	21.7 18
305	Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. <i>Current Opinion in Immunology</i> , 2016 , 39, 30-8	7.8 18
304	Do BRAF inhibitors select for populations with different disease progression kinetics?. <i>Journal of Translational Medicine</i> , 2013 , 11, 61	8.5 18
303	Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?. <i>Melanoma Research</i> , 2015 , 25, 461-9	3.3 18
302	A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9518-9518	2.2 18
301	Evolving impact of long-term survival results on metastatic melanoma treatment 2020 , 8,	18

300	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.. <i>Lancet, The</i> , 2022 ,	4.0	18
299	Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. <i>BMC Cancer</i> , 2019 , 19, 772	4.8	17
298	Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. <i>Oncology Reports</i> , 2011 , 25, 1495-502	3.5	17
297	Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. <i>BMC Cancer</i> , 2011 , 11, 451	4.8	17
296	Soluble interleukin-2 receptor in stage I-III melanoma. <i>Cytokine</i> , 2006 , 33, 150-5	4	17
295	Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3012-3012	2.2	17
294	Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability-high (MSI-H) tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 670-670	2.2	17
293	Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10005-10005	2.2	17
292	Phenotype characterization of human melanoma cells resistant to dabrafenib. <i>Oncology Reports</i> , 2017 , 38, 2741-2751	3.5	16
291	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020 , 8,	5.3	16
290	Sentinel lymph node biopsy in patients with cutaneous melanoma: outcome after 3-year follow-up. <i>European Journal of Surgical Oncology</i> , 2004 , 30, 440-3	3.6	16
289	Immunological phenotype analysis of patients with Fanconi's anaemia and their family members. <i>Acta Haematologica</i> , 1998 , 100, 39-43	2.7	16
288	LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study). <i>Annals of Oncology</i> , 2020 , 31, S1173-S1174	10.3	16
287	Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. <i>Journal of Translational Medicine</i> , 2019 , 17, 376	8.5	16
286	Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma. <i>Scientific Reports</i> , 2019 , 9, 7449	4.9	15
285	Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations 2019 , 7, 91		15
284	Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017 , 36, 180	12.8	15
283	Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 1395-1400	7.4	15

282	Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL). <i>Annals of Oncology</i> , 2016 , 27, vi379	10.3	15
281	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. <i>Current Oncology Reports</i> , 2019 , 21, 76	6.3	15
280	Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. <i>Journal of Molecular Diagnostics</i> , 2019 , 21, 756-767	5.1	15
279	SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 465, 331-8	5.1	15
278	Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. <i>JAMA Oncology</i> , 2020 , 6, 1957-1966	13.4	15
277	Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. <i>Journal of Translational Medicine</i> , 2020 , 18, 121	8.5	14
276	Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF mutation-positive melanoma. <i>British Journal of Cancer</i> , 2018 , 118, 777-784	8.7	14
275	Neoadjuvant therapy in melanoma: the next step?. <i>Lancet Oncology, The</i> , 2018 , 19, 151-153	21.7	14
274	Single versus combination immunotherapy drug treatment in melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 433-41	5.4	14
273	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2018 , 97, 59-61	7.5	14
272	New paradigm for stage III melanoma: from surgery to adjuvant treatment. <i>Journal of Translational Medicine</i> , 2019 , 17, 266	8.5	14
271	Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors. <i>World Journal of Surgical Oncology</i> , 2013 , 11, 36	3.4	14
270	Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. <i>Journal of Chemotherapy</i> , 2014 , 26, 193-201	2.3	14
269	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9524-9524	2.2	14
268	Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF mutation-positive melanoma receiving adjuvant vemurafenib. <i>Annals of Oncology</i> , 2020 , 31, 153-159	10.3	14
267	Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. <i>Journal of Translational Medicine</i> , 2019 , 17, 289	8.5	13
266	ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. <i>Cancers</i> , 2019 , 11,	6.6	13
265	Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. <i>Annals of Oncology</i> , 2016 , 27, vi379	10.3	13

264	Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2015 , 28, 442-52	4.5	13
263	Tumor biobanks in translational medicine. <i>Journal of Translational Medicine</i> , 2012 , 10, 204	8.5	13
262	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy 2020 , 8,		13
261	Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2512-2512	2.2	13
260	Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. <i>Annals of Oncology</i> , 2021 , 32, 917-925	10.3	13
259	Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced - or -mutated melanoma. <i>Oncotarget</i> , 2019 , 10, 1850-1859	3.3	12
258	Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immuno-oncology. <i>European Journal of Cancer</i> , 2019 , 112, 29-31	7.5	12
257	Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. <i>Journal of Translational Medicine</i> , 2015 , 13, 37	8.5	12
256	Who benefits most from adjuvant interferon treatment for melanoma?. <i>American Journal of Therapeutics</i> , 2015 , 22, 54-60	1	12
255	Impact of depth of response on survival in patients treated with cobimetinib + vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. <i>British Journal of Cancer</i> , 2019 , 121, 522-528	8.7	12
254	EGFR mutational status in penile cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 501-5	6.4	12
253	Molecular classification of patients with malignant melanoma for new therapeutic strategies. <i>Journal of Clinical Oncology</i> , 2007 , 25, e20-1	2.2	12
252	Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 44-50	7.4	12
251	Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma 2019 ,		12
250	Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS. <i>Medicina (Lithuania)</i> , 2020 , 56,	3.1	12
249	IL-6 modulation for COVID-19: the right patients at the right time? 2021 , 9,		12
248	Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1917-1920	4.3	11
247	The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer 2016 , 4,		11

246	Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 2015 , 3,		11
245	The role of optical radiations in skin cancer. <i>ISRN Dermatology</i> , 2013 , 2013, 842359		11
244	MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. <i>Journal of Human Genetics</i> , 2010 , 55, 518-24	4.3	11
243	The role of spectrophotometry in the diagnosis of melanoma. <i>BMC Dermatology</i> , 2010 , 10, 5	2.1	11
242	Prognostic value of CD40 in adult soft tissue sarcomas. <i>Clinical Cancer Research</i> , 2004 , 10, 2824-31	12.9	11
241	Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8573-8573	2.2	11
240	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600E mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9512-9512	2.2	11
239	Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. <i>European Journal of Dermatology</i> , 2018 , 28, 775-783	0.8	11
238	Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management. <i>Cancers</i> , 2020 , 12,	6.6	11
237	SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study 2021 , 9,		11
236	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021 , 9, 1202-1213	12.5	11
235	The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. <i>European Journal of Cancer</i> , 2021 , 155, 268-280	7.5	11
234	A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. <i>Melanoma Research</i> , 2017 , 27, 243-250	3.3	10
233	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report 2020 , 8,		10
232	MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	10
231	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) 2018 , 6, 69		10
230	Immune Checkpoint Inhibitors in Melanoma and HIV Infection. <i>Open AIDS Journal</i> , 2017 , 11, 91-100	0.6	10
229	Cosmic radiation and cancer: is there a link?. <i>Future Oncology</i> , 2015 , 11, 1123-35	3.6	10

228	Ran signaling in melanoma: implications for the development of alternative therapeutic strategies. <i>Cancer Letters</i> , 2015 , 357, 286-296	9.9	10
227	Mutation analysis of candidate genes in melanoma-prone families: evidence of different pathogenetic mechanisms at chromosome 9P21. <i>Melanoma Research</i> , 2003 , 13, 571-9	3.3	10
226	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101601	2.2	10
225	Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2517-2517	2.2	10
224	Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 487-487	2.2	10
223	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10012-10012	2.2	10
222	5-Year Outcomes with Cobimetinib plus Vemurafenib in Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. <i>Clinical Cancer Research</i> , 2021 ,	12.9	10
221	Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. <i>Frontiers in Oncology</i> , 2021 , 11, 670726	5.3	10
220	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1479-1489	5.4	10
219	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. <i>Cancers</i> , 2021 , 13,	6.6	10
218	The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. <i>Melanoma Research</i> , 2018 , 28, 333-340	3.3	10
217	Update on PEG-interferon β -2b as adjuvant therapy in melanoma. <i>Anticancer Research</i> , 2012 , 32, 3901-9	2.3	10
216	Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone. <i>Annals of Oncology</i> , 2016 , 27, vi379	10.3	9
215	Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. <i>International Journal of Oncology</i> , 2018 , 53, 1149-1159	4.4	9
214	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology</i> , 2015 , 16, 15-7	21.7	9
213	Late onset Blueberry Muffin Syndrome following congenital rubella. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003 , 17, 204-5	4.6	9
212	Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon. <i>Cancer</i> , 2000 , 89, 1490-4	6.4	9
211	The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21588-e21588	2.2	9

210	Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. <i>Oncotarget</i> , 2018 , 9, 12408-12417	3.3	9
209	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. <i>Future Oncology</i> , 2020 , 16, 2165-2175	3.6	9
208	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 655-664	21.7	9
207	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021 , 124, 574-580	8.7	9
206	Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. <i>Annals of Oncology</i> , 2018 , 29, viii413	10.3	9
205	MISIPI study: Melanoma ImmunoScore evaluation in patients treated with Ipilimumab. <i>Journal of Translational Medicine</i> , 2014 , 12, P11	8.5	8
204	Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients 2015 , 3, P186		8
203	Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. <i>Annals of Oncology</i> , 2008 , 19, 2092-3	10.3	8
202	Adjuvant treatment of malignant melanoma: where are we?. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 57, 45-52	7	8
201	Adjuvant therapy of cutaneous melanoma. <i>Lancet, The</i> , 1999 , 353, 328	40	8
200	Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20504-e20504	2.2	8
199	Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi. <i>Oncology Letters</i> , 2016 , 12, 1349-1354	5.4	8
198	Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. <i>Melanoma Management</i> , 2019 , 6, MMT30	2.1	8
197	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102253	14.4	8
196	FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1143-1151	7.4	7
195	Side effects and toxicities of targeted therapies in stage IV melanoma. <i>American Journal of Therapeutics</i> , 2015 , 22, 44-53	1	7
194	In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
193	melanoma and other skin tumours Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. <i>Annals of Oncology</i> , 2016 , 27, vi574	10.3	7

192	Immunoscore: a new possible approach for melanoma classification 2014 , 2,		7
191	3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. <i>European Journal of Cancer</i> , 2015 , 51, S667-S668	7.5	7
190	Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). <i>Oncologist</i> , 2017 , 22, 951-962	5.7	7
189	Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice. <i>Future Oncology</i> , 2015 , 11, 1429-35	3.6	7
188	Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report. <i>BMC Dermatology</i> , 2014 , 14, 15	2.1	7
187	Mutations in ERBB4 may have a minor role in melanoma pathogenesis. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 1685-7	4.3	7
186	Sentinel Lymph Node Biopsy to Stage Patients with Cutaneous Melanoma at the National Cancer Institute of Naples. Results from 240 Sentinel Node Biopsies. <i>Tumori</i> , 2002 , 88, S12-S13	1.7	7
185	Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAFV600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i 2018 ,		7
184	Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9530-9530	2.2	7
183	ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9599-TPS9599	2.2	7
182	The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600 mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10028-10028	2.2	7
181	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with -mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 5102-5112	12.9	7
180	Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis. <i>Journal of Translational Medicine</i> , 2021 , 19, 132	8.5	7
179	An open-label, multicentre safety study of vemurafenib in patients with BRAF-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019 , 107, 175-185	7.5	7
178	Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032. <i>Annals of Oncology</i> , 2018 , 29, viii725	10.3	7
177	Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). <i>Annals of Oncology</i> , 2018 , 29, viii737	10.3	7
176	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival 2021 , 9,		7
175	Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment.. <i>ESMO Open</i> , 2022 , 7, 100404	6	7

174	BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	6
173	Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. <i>Melanoma Management</i> , 2015 , 2, 41-50	2.1	6
172	Melanoma immunotherapy: strategies to overcome pharmacological resistance. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 289-304	3.5	6
171	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolimmunology</i> , 2020 , 9, 1710389	7.2	6
170	A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: potential applications in autoimmunity and cancer. <i>Human Immunology</i> , 2014 , 75, 730-9	2.3	6
169	Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. <i>Annals of Oncology</i> , 2015 , 26, vi74	10.3	6
168	Ipilimumab in the Treatment of Metastatic Melanoma: A Summary of Recent Studies. <i>Tumori</i> , 2013 , 99, e302-e305	1.7	6
167	Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls. <i>BMC Dermatology</i> , 2009 , 9, 7	2.1	6
166	MEK inhibition in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2012 , 367, 1364; author reply 1365	59.2	6
165	Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters. <i>Annals of Surgical Oncology</i> , 2004 , 11, 198S-202S	3.1	6
164	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9070-9070	2.2	6
163	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9584-9584	2.2	6
162	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , 2020 , 10, 1652	5.3	6
161	Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9507-9507	2.2	6
160	Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9516-9516	2.2	6
159	Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
158	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021 , 157, 250-258	7.5	6
157	Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF mutation-positive metastatic melanoma treated with vemurafenib + cobimetinib. <i>European Journal of Cancer</i> , 2019 , 116, 45-55	7.5	5

156	Immunotherapy in non-melanoma skin cancer: updates and new perspectives. <i>Drugs in Context</i> , 2019 , 8, 212583	5.2	5
155	Electrochemotherapy in melanoma patients: a single institution experience. <i>Melanoma Management</i> , 2015 , 2, 127-132	2.1	5
154	Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032. <i>Annals of Oncology</i> , 2017 , 28, v229-v230	10.3	5
153	The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients. <i>Annals of Oncology</i> , 2010 , 21, 1379-1380	10.3	5
152	Evidence of publication bias in clinical trials of biotherapies for solid tumors. <i>Cancer</i> , 2005 , 103, 653	6.4	5
151	Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9512-9512	2.2	5
150	Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600E mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9526-9526	2.2	5
149	Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9543-9543	2.2	5
148	Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAFV600-mutated metastatic melanoma (mM).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9556-9556	2.2	5
147	The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
146	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective 2020 , 8,		5
145	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021 , 148, 61-75	7.5	5
144	The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma. <i>Expert Opinion on Therapeutic Targets</i> , 2019 , 23, 53-68	6.4	5
143	Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. <i>Annals of Oncology</i> , 2018 , 29, viii456	10.3	5
142	MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies. <i>Annals of Oncology</i> , 2018 , 29, x4	10.3	5
141	Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. <i>Current Clinical Pharmacology</i> , 2018 , 13, 76-84 ^{2.5}		5
140	A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
139	Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?. <i>Current Opinion in Oncology</i> , 2021 , 33, 133-138	4.2	5

138	Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group. <i>International Journal of Oncology</i> , 2003 , 22, 1209-15	1	5
137	Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. <i>Future Oncology</i> , 2015 , 11, 1355-62	3.6	4
136	May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?. <i>Journal of Translational Medicine</i> , 2020 , 18, 489	8.5	4
135	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238). <i>Annals of Oncology</i> , 2017 , 28, v632-v633	10.3	4
134	3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC). <i>European Journal of Cancer</i> , 2015 , 51, S633	7.5	4
133	Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. <i>Melanoma Management</i> , 2015 , 2, 209-215	2.1	4
132	Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment. <i>Annals of Oncology</i> , 2000 , 11, 1504	10.3	4
131	Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9528-9528	2.2	4
130	Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. <i>Current Medicinal Chemistry</i> , 2020 , 27, 2792-2813	4.3	4
129	Identification of cases and estimate of direct costs of unresectable and advanced cutaneous squamous cell carcinoma: real-world data from a large Italian database. <i>British Journal of Dermatology</i> , 2020 , 183, 172-174	4	4
128	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists 2020 , 8,		4
127	Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization. <i>Cell Communication and Signaling</i> , 2020 , 18, 150	7.5	4
126	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. <i>Journal of Translational Medicine</i> , 2021 , 19, 17	8.5	4
125	Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. <i>Pigment Cell and Melanoma Research</i> , 2018 , 31, 516-522	4.5	4
124	Epigenetic Regulation in Melanoma: Facts and Hopes. <i>Cells</i> , 2021 , 10,	7.9	4
123	10360 Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047. <i>Annals of Oncology</i> , 2021 , 32, S867-S868 ^{10.3}		4
122	Enzyme activity of circulating CD73 in human serum. <i>Methods in Enzymology</i> , 2019 , 629, 257-267	1.7	3
121	Combination approaches and anti-PD1 therapies: the focus of new research at ESMO and SMR. <i>Melanoma Management</i> , 2015 , 2, 9-14	2.1	3

120	Biology confirmed but biomarkers elusive in melanoma immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 198-199	19.4	3
119	Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067). <i>Annals of Oncology</i> , 2017 , 28, v432-v433	10.3	3
118	The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. <i>Journal of Translational Medicine</i> , 2018 , 16, 101	8.5	3
117	Epidemiological and genetic factors underlying melanoma development in Italy. <i>Melanoma Management</i> , 2015 , 2, 149-163	2.1	3
116	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. <i>Expert Review of Dermatology</i> , 2013 , 8, 479-487		3
115	The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts.. <i>Cancers</i> , 2022 , 14,	6.6	3
114	Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9046-9046	2.2	3
113	A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS9106-TPS9106	2.2	3
112	Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9034-9034	2.2	3
111	Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9021-9021	2.2	3
110	Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9536-9536	2.2	3
109	SECOMBIT (sequential combo immuno and target therapy study): A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with unresectable, BRAF-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS9599-TPS9599	2.2	3
108	Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9596-TPS9596	2.2	3
107	CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9601-TPS9601	2.2	3
106	Anti-PD-1 antibody cetrelimab (JNJ-63723283) in patients with advanced cancers: Updated phase I/II study results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 31-31	2.2	3
105	Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. <i>European Journal of Cancer</i> , 2021 , 158, 225-233	7.5	3
104	1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone. <i>Annals of Oncology</i> , 2020 , 31, S734-S735	10.3	3
103	Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials. <i>Journal of Translational Medicine</i> , 2020 , 18, 294	8.5	3

102	No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study. <i>Oncology</i> , 2020 , 9, 1826132	7.2	3
101	Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave. <i>Journal of Translational Medicine</i> , 2021 , 19, 93	8.5	3
100	Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2021 , 26, 79-92	3.7	3
99	The Ratio of GrzB - FoxP3 over CD3 T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma. <i>Cancers</i> , 2021 , 13,	6.6	3
98	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). <i>Cancers</i> , 2021 , 13,	6.6	3
97	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. <i>European Journal of Cancer</i> , 2021 , 149, 37-48	7.5	3
96	How we treat locoregional melanoma. <i>ESMO Open</i> , 2021 , 6, 100136	6	3
95	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021 , 19, 270	8.5	3
94	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. <i>Melanoma Research</i> , 2021 , 31, 181-185	3.3	3
93	Selecting immuno-oncology-based drug combinations - what should we be considering?. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 971-985	3.8	3
92	Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients. <i>Journal of Translational Medicine</i> , 2015 , 13, O8	8.5	2
91	Vemurafenib beyond progression in a patient with metastatic melanoma: a case report. <i>Anti-Cancer Drugs</i> , 2015 , 26, 464-8	2.4	2
90	Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment. <i>Methods in Enzymology</i> , 2020 , 635, 21-31	1.7	2
89	Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma. <i>Annals of Oncology</i> , 2017 , 28, v442	10.3	2
88	The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018 2019 , 7, 221		2
87	Health-related quality of life in patients with fully resected BRAF mutation-positive melanoma receiving adjuvant vemurafenib. <i>European Journal of Cancer</i> , 2019 , 123, 155-161	7.5	2
86	Efficacy, Safety, and Quality of Life (QoL) Data from the Eortc 18071 Phase III Trial of Ipilimumab (Ipi) Versus Placebo After Complete Resection of Stage III Melanoma. <i>Annals of Oncology</i> , 2014 , 25, iv375	10.3	2
85	The European Ipilimumab Expanded Access Programme (EAP): Efficacy and Safety Data from the Italian Cohort of Patients with Pretreated, Advanced Melanoma. <i>Annals of Oncology</i> , 2012 , 23, ix367-ix368	10.3	2

84	The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg 2013 , 1,		2
83	Circulating melanoma-associated markers detected by RT-PCR in patients with classic Kaposi's sarcoma. <i>Annals of Oncology</i> , 2000 , 11, 635-6	10.3	2
82	PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.. <i>Future Oncology</i> , 2022 ,	3.6	2
81	Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (mut) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8518-8518	2.2	2
80	NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9102-TPS9102	2.2	2
79	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9526-9526	2.2	2
78	Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9532-9532	2.2	2
77	Adverse events of special interest in the phase 3 COLUMBUS study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9567-9567	2.2	2
76	Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies. <i>Tumori</i> , 2013 , 99, 302e-5e	1.7	2
75	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. <i>Frontiers in Oncology</i> , 2021 , 11, 672797	5.3	2
74	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.. <i>European Journal of Cancer</i> , 2021 , 162, 22-33	7.5	2
73	The Future of Melanoma Therapy is the Combination Approach. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2011 , 02,	2	2
72	The clinical and translational research activities at the INT - IRCCS "Fondazione Pascale" cancer center (Naples, Italy) during the COVID-19 pandemic. <i>Infectious Agents and Cancer</i> , 2020 , 15, 69	3.5	2
71	Comparison of Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
70	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). <i>Journal of Translational Medicine</i> , 2020 , 18, 346	8.5	2
69	Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2565-2565	2.2	2
68	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021 , 151, 72-83	7.5	2
67	Nivolumab for the treatment of small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2020 , 14, 5-13	3.8	2

66	Elevated Levels of Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-17	3.6	2
65	Effects of Molecular Heterogeneity on Survival of Patients With -Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-18	3.6	2
64	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021 , 152, 116-128	7.5	2
63	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. <i>European Journal of Cancer</i> , 2021 , 153, 168-178	7.5	2
62	Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. <i>Future Oncology</i> , 2020 , 16, 1091-1100	3.6	1
61	Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors 2018 , 565-578		1
60	Quality assurance in melanoma care: The EU-MELACARE study. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1773-1778	3.6	1
59	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. <i>Journal of Translational Medicine</i> , 2018 , 16,	8.5	1
58	Molecular Mechanisms Underlying the Action of Ipilimumab Against Metastatic Melanoma 2018 , 85-96		1
57	Combination therapies in advanced melanoma. <i>Melanoma Management</i> , 2014 , 1, 47-56	2.1	1
56	Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer 2014 , 2, 15		1
55	Melanoma pathophysiology and drug targets 2012 , 6-17		1
54	Melanoma: from research to treatment. <i>Journal of Skin Cancer</i> , 2011 , 2011, 710697	1.4	1
53	Low doses interferon-alpha in the treatment of high-risk cutaneous melanoma. Melanoma Cooperative Group. <i>Annals of Oncology</i> , 2000 , 11, 487-90	10.3	1
52	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	1
51	A Metabolomics-Based Screening Proposal for Colorectal Cancer.. <i>Metabolites</i> , 2022 , 12,	5.6	1
50	Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors.. <i>Frontiers in Immunology</i> , 2022 , 13, 811131	8.4	1
49	Immunoscore as new possible approach for the classification of melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20020-e20020	2.2	1

48	Expansion of a lymphocyte subset expressing a spliced FKBP51 isoform in melanoma patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20070-e20070	2.2	1
47	Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9533-9533	2.2	1
46	Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600E mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9515-9515	2.2	1
45	Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600E mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10034-10034	2.2	1
44	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. <i>European Journal of Cancer</i> , 2021 ,	7.5	1
43	Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
42	Letter Regarding Editorial by Samuel Zagarella. <i>American Journal of Dermatopathology</i> , 2021 , 43, 539-540.	0.9	1
41	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma 2019 , 1-27		1
40	The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019 2020 , 8,		1
39	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , 2021 , 19, 142	8.5	1
38	Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19. <i>Annals of Oncology</i> , 2021 , 32, 674-676	10.3	1
37	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). <i>Journal of Translational Medicine</i> , 2021 , 19, 238	8.5	1
36	Are there, or shall we discover, biomarkers to guide PD-1 inhibition?. <i>Immunotherapy</i> , 2016 , 8, 681-6	3.8	1
35	The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. <i>Journal of Translational Medicine</i> , 2020 , 18, 171	8.5	1
34	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). <i>Journal of Translational Medicine</i> , 2021 , 19, 13	8.5	1
33	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. <i>Journal of Translational Medicine</i> , 2021 , 19, 70	8.5	1
32	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. <i>International Journal of Cancer</i> , 2021 , 149, 1926-1934	7.5	1
31	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 , 89, 499	3.5	1

30	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.. <i>Journal of Translational Medicine</i> , 2022 , 20, 159	8.5	1
29	CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.. <i>New England Journal of Medicine</i> , 2022 , 386, 1668-1669	59.2	1
28	Concomitant type 2 diabetes mellitus (T2DM) in metastatic melanoma patients could be related to lower level of Lag-3: a transcriptomic analysis on retrospective cohort.. <i>Annals of Oncology</i> , 2022 ,	10.3	0
27	Cost of illness of cutaneous squamous cell carcinoma (CSCC). <i>Global & Regional Health Technology Assessment</i> , 2020 , 7, 148-153	0.2	0
26	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply. <i>Lancet Oncology</i> , 2021 , 22, e343-e344	21.7	0
25	Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.. <i>Scientific Reports</i> , 2022 , 12, 5448	4.9	0
24	Prognostic and predictive value of #blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.. <i>European Journal of Cancer</i> , 2022 , 165, 97-112	7.5	0
23	Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.. <i>European Journal of Cancer</i> , 2022 , 169, 188-197	7.5	0
22	Economic Evaluation of Ipilimumab in First Line Treatment of Advanced Melanoma in Italy. <i>Global & Regional Health Technology Assessment</i> , 2016 , 3, GRHTA.5000230	0.2	
21	Advances in immunotherapy for melanoma. <i>Melanoma Management</i> , 2014 , 1, 19-24	2.1	
20	Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies. <i>Cancer Drug Discovery and Development</i> , 2015 , 245-258	0.3	
19	Molecular Pathogenesis of Melanoma: Established and Novel Pathways 2012 , 19-37		
18	Detection of tyrosinase mRNA in tumor tissue microdissections from classic Kaposi's sarcoma. <i>Annals of Oncology</i> , 2001 , 12, 1765-6	10.3	
17	Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont . 2022 , 10,		
16	Mobile hospital rooms to fight melanoma. <i>Melanoma Research</i> , 2001 , 11, 83-4	3.3	
15	Mutation frequencies in a gene panel among primary tumors and metastases in patients with melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21554-e21554	2.2	
14	Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS145-TPS145	2.2	
13	Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2559-2559	2.2	

- 12 The ACC melanoma pilot project: Real-world evaluation of an NGS platform for molecular characterization of melanoma in Italy.. *Journal of Clinical Oncology*, **2019**, 37, e14600-e14600 2.2
- 11 Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma **2020**, 1215-1241
- 10 BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustine.. *Journal of Clinical Oncology*, **2014**, 32, TPS9109-TPS9109 2.2
- 9 Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.. *Journal of Clinical Oncology*, **2014**, 32, TPS9105-TPS9105 2.2
- 8 Mutation analysis of mucosal and cutaneous melanomas during progression.. *Journal of Clinical Oncology*, **2017**, 35, e21047-e21047 2.2
- 7 Marker utility for combination therapy. *Methods in Molecular Biology*, **2014**, 1102, 97-115 1.4
- 6 Reply to E. Hindi. *Journal of Clinical Oncology*, **2021**, 39, 944-946 2.2
- 5 The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020. *Journal of Translational Medicine*, **2021**, 19, 144 8.5
- 4 Immunotherapies and Novel Combinations **2019**, 643-653
- 3 Dermatologic adverse events associated with targeted therapies for melanoma. *Expert Opinion on Drug Safety*, **2021**, 1-11 4.1
- 2 The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.. *Journal of Translational Medicine*, **2022**, 20, 179 8.5
- 1 The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.. *Journal of Translational Medicine*, **2022**, 20, 200 8.5